Cargando…
Prognostic value of sarcopenia in patients with lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors or immune checkpoint inhibitors
OBJECTIVES: It remains controversial whether sarcopenia has any significant impact on the efficacy of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) or immune checkpoint inhibitors (ICIs) in patients with advanced non-small cell lung cancer (NSCLC). Therefore, in this study,...
Autores principales: | Lyu, Jiahua, Yang, Ningjing, Xiao, Ling, Nie, Xinyu, Xiong, Jing, Liu, Yudi, Zhang, Min, Zhang, Hangyue, Tang, Cunhan, Pan, Shiyi, Liang, Long, Bai, Hansong, Li, Churong, Kuang, Hao, Li, Tao |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10031770/ https://www.ncbi.nlm.nih.gov/pubmed/36969820 http://dx.doi.org/10.3389/fnut.2023.1113875 |
Ejemplares similares
-
Post-treatment serum triglyceride: An effective biomarker for body fat mass and overall survival in esophageal squamous cell cancer patients treated with chemoradiotherapy
por: Lyu, Jiahua, et al.
Publicado: (2022) -
Sarcopenia Was a Poor Prognostic Predictor for Patients With Advanced Lung Cancer Treated With Immune Checkpoint Inhibitors
por: Li, Shuluan, et al.
Publicado: (2022) -
Low geriatric nutritional risk index as a poor prognostic biomarker for immune checkpoint inhibitor treatment in solid cancer
por: Zhang, Lilong, et al.
Publicado: (2023) -
Transarterial Chemoembolization Combined with Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors versus Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors for Advanced Hepatocellular Carcinoma
por: Huang, Jin-Tao, et al.
Publicado: (2022) -
Obesity, Sarcopenia, and Outcomes in Non-Small Cell Lung Cancer Patients Treated With Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors
por: Khaddour, Karam, et al.
Publicado: (2020)